FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016291258> ?p ?o ?g. }

• W2016291258 endingPage "572" @default.
• W2016291258 startingPage "567" @default.
• W2016291258 abstract "Serial circulating tumor cell (CTC) counts have demonstrated predictive and prognostic value in patients with metastatic breast, colorectal, and prostate cancer. In a phase III study of pegylated liposomal doxorubicin (PLD) with trabectedin vs. PLD for relapsed ovarian cancer, we evaluated the correlation, if any, between numbers of CTCs and progression free survival, (PFS) and overall survival (OS).CTCs were isolated from peripheral blood (10 mL) using the CellSearch system and reagents (Veridex). A CTC is defined as EpCAM+, cytokeratin+, CD45-, and is positive for the nuclear stain DAPI. The normal reference range for CellSearch is <2 CTC/7.5 mL of blood. Hazard ratios adjusted for known prognostic factors were estimated by Cox regression.Two-hundred sixteen patients had baseline CTC measurements of which 111 (51.4%) were randomized to the trabectedin+PLD arm; 143/216 patients (66.2%) were platinum-sensitive. Thirty-one of 216 patients (14.4%) had 2 or more CTCs detected prior to the start of therapy (range 2-566). Univariate Cox regression analyses indicated that patients with ≥2 CTCs prior to therapy had 1.89- (p=0.003) and 2.06-fold (p=0.003) higher risk for progression and death respectively. Multivariate analyses that include baseline CA-125, platinum sensitivity status, largest diameter lesion, number of tumor lesions, ECOG PS, and tumor grade show that patients with elevated baseline CTC had 1.58- (p=0.058) and 1.54-fold (p=0.096) higher risk for progression and death respectively.Results from this study indicate that elevated numbers of CTCs impart an unfavorable prognosis for ovarian cancer patients." @default.
• W2016291258 created "2016-06-24" @default.
• W2016291258 creator A5000978310 @default.
• W2016291258 creator A5014611244 @default.
• W2016291258 creator A5033205363 @default.
• W2016291258 creator A5050026123 @default.
• W2016291258 creator A5056376840 @default.
• W2016291258 creator A5062396254 @default.
• W2016291258 creator A5062762491 @default.
• W2016291258 creator A5077016336 @default.
• W2016291258 creator A5080782271 @default.
• W2016291258 creator A5081381927 @default.
• W2016291258 date "2011-09-01" @default.
• W2016291258 modified "2023-09-27" @default.
• W2016291258 title "Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer" @default.
• W2016291258 cites W1991770526 @default.
• W2016291258 cites W1998258610 @default.
• W2016291258 cites W2028911568 @default.
• W2016291258 cites W2038554735 @default.
• W2016291258 cites W2051227781 @default.
• W2016291258 cites W2062101197 @default.
• W2016291258 cites W2066442082 @default.
• W2016291258 cites W2087479328 @default.
• W2016291258 cites W2098585582 @default.
• W2016291258 cites W2099367648 @default.
• W2016291258 cites W2100115202 @default.
• W2016291258 cites W2101995865 @default.
• W2016291258 cites W2111976640 @default.
• W2016291258 cites W2116483002 @default.
• W2016291258 cites W2119299101 @default.
• W2016291258 cites W2125064537 @default.
• W2016291258 cites W2126236874 @default.
• W2016291258 cites W2128571346 @default.
• W2016291258 cites W2138665978 @default.
• W2016291258 cites W2138933035 @default.
• W2016291258 cites W2144769242 @default.
• W2016291258 cites W2148998801 @default.
• W2016291258 cites W2154175915 @default.
• W2016291258 cites W2156804105 @default.
• W2016291258 cites W2168598691 @default.
• W2016291258 cites W2330647671 @default.
• W2016291258 cites W3041047318 @default.
• W2016291258 doi "https://doi.org/10.1016/j.ygyno.2011.05.028" @default.
• W2016291258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21664658" @default.
• W2016291258 hasPublicationYear "2011" @default.
• W2016291258 type Work @default.
• W2016291258 sameAs 2016291258 @default.
• W2016291258 citedByCount "147" @default.
• W2016291258 countsByYear W20162912582012 @default.
• W2016291258 countsByYear W20162912582013 @default.
• W2016291258 countsByYear W20162912582014 @default.
• W2016291258 countsByYear W20162912582015 @default.
• W2016291258 countsByYear W20162912582016 @default.
• W2016291258 countsByYear W20162912582017 @default.
• W2016291258 countsByYear W20162912582018 @default.
• W2016291258 countsByYear W20162912582019 @default.
• W2016291258 countsByYear W20162912582020 @default.
• W2016291258 countsByYear W20162912582021 @default.
• W2016291258 countsByYear W20162912582022 @default.
• W2016291258 countsByYear W20162912582023 @default.
• W2016291258 crossrefType "journal-article" @default.
• W2016291258 hasAuthorship W2016291258A5000978310 @default.
• W2016291258 hasAuthorship W2016291258A5014611244 @default.
• W2016291258 hasAuthorship W2016291258A5033205363 @default.
• W2016291258 hasAuthorship W2016291258A5050026123 @default.
• W2016291258 hasAuthorship W2016291258A5056376840 @default.
• W2016291258 hasAuthorship W2016291258A5062396254 @default.
• W2016291258 hasAuthorship W2016291258A5062762491 @default.
• W2016291258 hasAuthorship W2016291258A5077016336 @default.
• W2016291258 hasAuthorship W2016291258A5080782271 @default.
• W2016291258 hasAuthorship W2016291258A5081381927 @default.
• W2016291258 hasConcept C121608353 @default.
• W2016291258 hasConcept C126322002 @default.
• W2016291258 hasConcept C126894567 @default.
• W2016291258 hasConcept C143998085 @default.
• W2016291258 hasConcept C207103383 @default.
• W2016291258 hasConcept C2776694085 @default.
• W2016291258 hasConcept C2779013556 @default.
• W2016291258 hasConcept C2780192828 @default.
• W2016291258 hasConcept C2780427987 @default.
• W2016291258 hasConcept C2780739268 @default.
• W2016291258 hasConcept C44249647 @default.
• W2016291258 hasConcept C50382708 @default.
• W2016291258 hasConcept C61238886 @default.
• W2016291258 hasConcept C71924100 @default.
• W2016291258 hasConceptScore W2016291258C121608353 @default.
• W2016291258 hasConceptScore W2016291258C126322002 @default.
• W2016291258 hasConceptScore W2016291258C126894567 @default.
• W2016291258 hasConceptScore W2016291258C143998085 @default.
• W2016291258 hasConceptScore W2016291258C207103383 @default.
• W2016291258 hasConceptScore W2016291258C2776694085 @default.
• W2016291258 hasConceptScore W2016291258C2779013556 @default.
• W2016291258 hasConceptScore W2016291258C2780192828 @default.
• W2016291258 hasConceptScore W2016291258C2780427987 @default.
• W2016291258 hasConceptScore W2016291258C2780739268 @default.
• W2016291258 hasConceptScore W2016291258C44249647 @default.
• W2016291258 hasConceptScore W2016291258C50382708 @default.
• W2016291258 hasConceptScore W2016291258C61238886 @default.

• next